Update: CDC recommendations for managing and reporting <i>Shigella</i> infections with possible reduced susceptibility to ciprofloxacin

CDC has issued a Health Alert Network Update with recommendations for the management and reporting of <i>Shigella</i> infections that have been treated with ciprofloxacin or azithromycin and had possible clinical treatment failure.

CDC has issued a Health Alert Network Update with recommendations for the management and reporting of <i>Shigella</i> infections that have been treated with ciprofloxacin or azithromycin and had possible clinical treatment failure. The agency reports that it is continuing to see a growing number of <i>Shigella</i> isolates that test within the susceptibility range for ciprofloxacin, a fluoroquinolone antibiotic, but harbor at least one resistance mechanism. CDC said it "remains concerned about potential clinical failures with fluoroquinolone treatment." Patients with <i>Shigella</i> infections who require fluoroquinolones should be carefully monitored, and any possible treatment failures should be reported. In addition, CDC reports it has seen an increasing number of <i>Shigella</i> isolates with azithromycin minimum inhibitory concentrations that exceed the epidemiological cutoff value. Any possible treatment failures among patients with <i>Shigella</i> infections treated with azithromycin should be reported. This report is a followup to a <a href="https://emergency.cdc.gov/han/han00401.asp&quot; target="_blank">health advisory</a> issued in April 2017.